Concepedia

Concise Drug Review: Azacitidine and Decitabine

Ellen J. B. Derissen, Jos H. Beijnen, Jan H.M. Schellens

The Oncologist · 2013 · 294 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.

References

32

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

, , +9

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2002 · 1.8K citations

, , +16

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

, , +9

Decitabine improves patient outcomes in myelodysplastic syndromes

Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld et al. · Cancer · 2006 · 1.5K citations

, , +14

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

, , +15